Parataxis Holdings LLC has agreed to invest nearly $18.3 million (KRW 25 billion) in South Korea’s Bridge Biotherapeutics, gaining a controlling stake and rebranding the company as Parataxis Korea.
Digital Shift: Parataxis Capital Bets on BTC Strategy in Korean Markets
This article was published more than a year ago. Some information may no longer be current.
WRITTEN BY
SHARE
Once finalized, the deal will establish the first Bitcoin-native treasury platform in the South Korean public markets, leveraging the digital asset expertise of Parataxis Capital. Leadership changes include Edward Chin and Andrew Kim joining the board, with Kim taking over as CEO. The move reflects growing global institutional interest in BTC treasury strategies. The deal is pending shareholder approval, with further details expected in August.
